2024/2025 Questions With Verified
Solutions
1. pharmacologic agents for PTSD - ANS -med tx is focused on
diminishing intrusive thoughts, hyperarousal, and avoidance, with
some success and mixed results
2. PTSD frequent comorbidity - ANS -depressive disorder, anxiety
disorders, and behavioral problems associated with
______________
3. sertraline and paroxetine - ANS -that __________and
______________ are approved by the Food and Drug
Administration (FDA) in the treatment of PTSD in adults, there is
, scant evidence to support its use for the core symptoms of PTSD
in youth
4. Risperidone and aripiprazole - ANS -FDA approval for use in
children and adolescents with aggression, severe behavioral
dyscontrol, and severe psychiatric disorders
5. Antiadrenergic agents - ANS -treat dysregulation of the
noradrenergic system in adults and youth with PTSD
6. clonidine and guanfacine - ANS -Alpha2-agonists examples
7. Alpha2 agonists - ANS -decrease norepinephrine release, such as,
are
,8. propranolol - ANS -centrally acting β-antagonists example
9. prazosin - ANS -α-1-antagonists example
10. propranolol use - ANS -hypothesized to improve
hyperarousal and intrusive thoughts through attenuation of
norepinephrine postsynaptically
11. prazosin use - ANS -nightmares associated with trauma
12. Modify PTSD sx - ANS -Off-label medications including
antidepressants, atypical antipsychotics, adrenergic
modulators/sympatholytics, and anticonvulsants/mood stabilizers
, 13. clonidine and propanolol - ANS -nightmares and
exaggerated startle response: some evidence in adults, but
children case report only
14. guanfacine and clonidine - ANS -__________ may reduce
nightmares in children with PTSD and ____________may diminish
symptoms of reenactment of traumatic events in children
15. Mood-stabilizing agents - ANS -divalproex, carbamazepine,
topiramate, and gabapentin have been utilized for adults with
PTSD with modest improvement; some
16. clonidine with dosage ranges of 0.05 to 0.1 mg twice daily -
ANS -may provide some relief for the symptoms of hyperarousal,